CN105148039A - 一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 - Google Patents
一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 Download PDFInfo
- Publication number
- CN105148039A CN105148039A CN201510718052.7A CN201510718052A CN105148039A CN 105148039 A CN105148039 A CN 105148039A CN 201510718052 A CN201510718052 A CN 201510718052A CN 105148039 A CN105148039 A CN 105148039A
- Authority
- CN
- China
- Prior art keywords
- radix
- fructus
- rhizoma
- immersion
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006187 pill Substances 0.000 title claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title abstract description 54
- 238000006243 chemical reaction Methods 0.000 title abstract description 10
- 238000001959 radiotherapy Methods 0.000 claims abstract description 28
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 16
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 15
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 27
- 238000007654 immersion Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 239000009636 Huang Qi Substances 0.000 claims description 18
- 241000218176 Corydalis Species 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 15
- 244000113306 Monascus purpureus Species 0.000 claims description 14
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 14
- 229940057059 monascus purpureus Drugs 0.000 claims description 14
- 239000009526 Fructus Akebiae Substances 0.000 claims description 13
- 238000010410 dusting Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 210000002615 epidermis Anatomy 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 235000019991 rice wine Nutrition 0.000 claims description 6
- 239000000052 vinegar Substances 0.000 claims description 6
- 235000021419 vinegar Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 235000014101 wine Nutrition 0.000 claims description 5
- 241000209094 Oryza Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 33
- 210000004185 liver Anatomy 0.000 abstract description 27
- 210000003734 kidney Anatomy 0.000 abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 240000004510 Agastache rugosa Species 0.000 abstract 1
- 244000036770 Akebia trifoliata Species 0.000 abstract 1
- 235000012980 Akebia trifoliata Nutrition 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000830532 Corydalis yanhusuo Species 0.000 abstract 1
- 241001523681 Dendrobium Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000037826 Polygonatum kingianum Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000007215 black sesame Nutrition 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 229940026314 red yeast rice Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 52
- 239000008280 blood Substances 0.000 description 52
- 210000004072 lung Anatomy 0.000 description 24
- 230000001737 promoting effect Effects 0.000 description 22
- 230000017531 blood circulation Effects 0.000 description 21
- 210000002216 heart Anatomy 0.000 description 21
- 210000002784 stomach Anatomy 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 19
- 235000009508 confectionery Nutrition 0.000 description 19
- 230000036407 pain Effects 0.000 description 18
- 230000007812 deficiency Effects 0.000 description 17
- 206010011224 Cough Diseases 0.000 description 15
- 206010033557 Palpitations Diseases 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 14
- 206010047700 Vomiting Diseases 0.000 description 12
- 241000411851 herbal medicine Species 0.000 description 12
- 208000002173 dizziness Diseases 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 230000008673 vomiting Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000035922 thirst Effects 0.000 description 9
- 230000002936 tranquilizing effect Effects 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 230000035619 diuresis Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000008454 Hyperhidrosis Diseases 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 206010003549 asthenia Diseases 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 206010061428 decreased appetite Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000035900 sweating Effects 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000015220 Febrile disease Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000009429 distress Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000003014 reinforcing effect Effects 0.000 description 5
- 230000004206 stomach function Effects 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 208000005946 Xerostomia Diseases 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000552 rheumatic effect Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000036119 Frailty Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000017574 dry cough Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010058117 Ocular icterus Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010064921 Urinary tract inflammation Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000292 leukogenic effect Effects 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于缓解肿瘤放疗后反应的中药药丸及制备方法,属中药领域。本发明药物有效成分的原料组成及重量份数为:麦冬、太子参、大枣、生地、龙眼肉、山萸肉、白术、黄精、枸杞子、茯苓、黑芝麻、当归、川芎、夜交藤、柏子仁、黄芪、延胡索、五味子、石斛、牡丹皮、八月札、红曲、藿香、甘草、鱼腥草。本发明选用药材药性相适相辅,针对病因对症下药,有补益肝肾、健脾益气、和胃止呕、活血祛瘀、滋阴清热、清热解毒、理气止痛、养心安神之功效,吸收效果好,疗效显著,无毒副作用及临床不良反应,经临床验证对肿瘤放疗后的毒副反应治疗效果较好。
Description
所属技术领域
本发明涉及中药领域,尤其涉及一种用于缓解肿瘤放疗后反应的中药药丸及制备方法。
背景技术
放疗就是放射治疗,指利用射线对细胞的杀伤作用来杀死体内恶变的细胞,从而达到治疗恶性肿瘤的目的。放射治疗是一种针对肿瘤的物理疗法,现已成为治疗恶性肿瘤的一个重要手段,对于许多癌症可以产生较好效果。放疗可以迅速作用于局部或全身,近期治疗效果较好,但是放疗副作用也很大,它们在杀伤肿瘤细胞的同时,也杀伤正常组织的细胞,而这些细胞与组织是人体重要的免疫防御系统,破坏了人体的免疫系统,癌细胞就可能迅速发展,导致病情加重,甚至缩短患者的生命。放疗后病人可出现一系列局部和全身的不良反应,表现为虚弱、乏力、头晕、头痛、厌食,个别有恶心、呕吐等,特别是腹部照射和大面积照射时,反应较重。
放疗后病人可出现一系列局部和全身的不良反应,表现为虚弱、乏力、头晕、头痛、厌食,个别有恶心、呕吐等,特别是腹部照射和大面积照射时,反应较重。目前西医一般对症治疗,或服用一些止痛及抗生素类药物予以治疗,并无特效药物,而且副作用大,具有一定的药物依赖性。
中医认为,放疗导致的机体损害称为“火邪热毒”,因此养阴清热是放疗后中医调养的大原则。本发明所述的药丸是经长期的临床验证总结而成,针对病因对症下药,具有补益肝肾、健脾益气、和胃止呕、活血祛瘀、滋阴清热、清热解毒、理气止痛、养心安神之功效,可扶正固本、补气养血,提高机体免疫力,改善血液循环,缓解放疗毒副反应,减轻患者痛苦,提高生存质量,达到彻底康复的目的。
发明内容
本发明提供了一种用于缓解肿瘤放疗后反应的中药药丸及制备方法,具有补益肝肾、健脾益气、和胃止呕、活血祛瘀、滋阴清热、清热解毒、理气止痛、养心安神之功效,治病求源标本兼治,对各种肿瘤放疗后反应均具有很好的疗效。
为实现上述目的,本发明的技术方案实施如下:
一种用于缓解肿瘤放疗后反应的中药药丸,制成所述药物有效成分的原料组成及重量份数为:
麦冬65~82g太子参62~78g大枣59~75g生地55~72g龙眼肉52~68g
山萸肉48~65g白术45~61g黄精43~57g枸杞子40~55g茯苓37~52g
黑芝麻35~49g当归32~46g川芎29~43g夜交藤27~40g柏子仁25~37g
黄芪22~35g延胡索20~32g五味子18~28g石斛15~25g牡丹皮12~21g
八月札10~18g红曲8~15g藿香5~12g甘草3~8g鱼腥草1~5g
制成所述药物有效成分的原料组成及重量份数为:
麦冬68~78g太子参65~75g大枣62~72g生地58~68g龙眼肉55~65g
山萸肉51~62g白术48~57g黄精46~54g枸杞子43~52g茯苓40~49g
黑芝麻38~46g当归35~43g川芎32~40g夜交藤30~37g柏子仁28~34g
黄芪25~32g延胡索23~29g五味子21~25g石斛18~22g牡丹皮15~19g
八月札12~16g红曲10~13g藿香7~10g甘草4~6g鱼腥草2~4g
制成所述药物有效成分的原料组成及重量份数为:
麦冬75g太子参72g大枣68g生地64g龙眼肉61g
山萸肉58g白术54g黄精51g枸杞子48g茯苓45g
黑芝麻42g当归38g川芎35g夜交藤33g柏子仁31g
黄芪28g延胡索25g五味子23g石斛20g牡丹皮17g
八月札14g红曲12g藿香8g甘草5g鱼腥草3g
一种用于缓解肿瘤放疗后反应的中药药丸的制备方法,包括以下工艺步骤:
(1)将麦冬、太子参、大枣、生地、山萸肉、黄精、黑芝麻、夜交藤、石斛、牡丹皮、八月札、红曲、藿香、甘草、鱼腥草洗净、晾干后混合均匀,放入容器中,在容器中加入6~8倍量的水,加热煮沸2~3小时,冷却后取浸液;在剩余的药渣中再加入4~6倍量的水,加热煮沸1~2小时,冷却后浸液;合并两次所得浸液,加热,蒸发浓缩为相对密度1.15~1.25的稠膏,备用;
(2)将龙眼肉、枸杞子、茯苓、当归、五味子放入容器中,加入3~5倍量的绍兴黄酒,煮沸后放凉,继续浸泡3~5小时,取浸液;在剩余的药渣中再加入2~4倍量的绍兴黄酒,煮沸后放晾,继续浸泡2~4小时,取浸液;合并两次所得浸液,加蒸蒸发浓缩为相对密度1.10~1.20的稠膏,备用;
(3)将白术、川芎放入铁锅中,文火微炒,炒至表皮变黄后,喷洒即墨老酒,继续炒至表皮焦黄后,取出放凉,粉碎研末,过120目细筛,得细粉,备用;
(4)取黄芪洗净,加定量的米醋拌匀,闷润至醋被吸尽后,置炒制容器内,用文火加热炒干,取出晾凉。筛去碎屑,粉碎研末,过120目细筛,得细粉,备用;
(5)将延胡索洗净晾干,加定量的黄酒拌匀,闷透,文火加热,炒干,取出放凉,粉碎研末,过120目细筛,得细粉,备用;
(6)将柏子仁洗净烘干,粉碎研末,过120目细筛,得细粉,备用;
(7)将步骤(1)、步骤(2)所得的稠膏,与步骤(3)、步骤(4)、步骤(5)、步骤(6)中所得的细粉混合,加入炼蜜搅拌均匀后,制备为每粒8g的药丸。
本发明所用中药的药性如下:
麦冬:味甘;微苦;性微寒。归心;肺;胃经。养阴生津;润肺清心。主治肺燥干咳,阴虚痨嗽,喉痹咽痛,津伤口渴,内热消渴,心烦失眠,肠燥便秘。《名医别录》载:“麦冬疗身重目黄,心下支满,虚劳客热,口干烦渴,止呕吐,愈痿蹶,强阴益精,消谷调中,保神,定肺气,安五脏,令人肥健。”现代医学研究证实,麦冬含有多种甾体皂甙、胡萝卜素、粘液质、糖类、豆甾醇等成分,有升高白细胞,延长抗体存在时间的作用,同时提高免疫功能和核酸合成率,促进抗体、补体、干扰素、溶菌酶等免疫物质的产生,有增强正气、加强抗邪作用。
太子参:味甘;微苦;性微寒。归脾、肺经。补益脾肺;益气生津。主治脾胃虚弱;食欲不振;倦怠无力;气阴两伤;干咳痰少;自汗气短;以及温病后期气虚津伤;内热口渴;或神经衰弱,心悸失眠,头昏健忘,小儿夏季热。《陕西中草药》:补气益血,健脾生津。治病后体虚,肺虚咳嗽,脾虚腹泻,小儿虚汗,心悸,口干,不思饮食。现代医学研究证明:太子参对机体具有适应原样作用,即能增强机体对各种有害刺激的防御能力,还可增强人体内的物质代谢。
大枣:味甘;温。归脾;胃经。补脾胃;益气血;安心神;调营卫;和药性。主治脾胃虚弱;气血不足;食少便溏;倦怠乏力;心悸失眠;妇人脏躁;营卫不和。《本草汇言》:沈氏曰,此药甘润膏凝,善补阴阳、气血、津液、脉络、筋俞、骨髓,一切虚损,无不宜之。如龙谭方治惊悸怔忡,健忘恍惚,志意昏迷,精神不守,或中气不和,饮食无味,百体懒重,肌肉瘦,此属心、脾二藏元神亏损之证,必用大枣治之。佐用陈皮,调畅中脘虚滞之痰。
生地:味甘;苦;性微寒。归心;肝;肾经。滋阴清热;凉血补血。主治热病烦渴;内热消渴;骨蒸劳热;温病发斑;血热所致的吐血;崩漏;尿血;便血;血虚萎黄;眩晕心悸;血少经闭。《日华子本草》载:“治惊悸劳劣,心肺损,吐血,鼻衄,妇人崩中血晕,助筋骨。”现代医学研究证实,生地是有效的免疫增强剂,包含对人体有好处的多类氨基酸、糖类,并且有强心、利尿、降压、降糖、保肝、抑菌、升高血细胞等药理作用。
龙眼肉:味甘;性温。入心;肾;肝;脾经。补心脾;益气血;安心神。主治心脾两虚、气血不足所致的惊悸;怔忡;失眠;健忘;血虚萎黄;月经不调;崩漏。《得配本草》载:“益脾胃,葆心血,润五脏,治怔忡。”现代医学研究证实,龙眼肉对心肌遭受低温、高温和缺氧刺激有明显的保护作用,对奥杜盎氏小芽胞癣菌有抑制作用,此外还有镇静和健胃作用。
山萸肉:味酸;性微温,归肝;肾经。补益肝肾;收敛固脱,主治:腰头晕目眩;耳聋耳鸣;腰膝酸软;跹精滑精;小便频数;虚汗不止;妇女崩漏。《医学入门》:山茱萸本涩剂也,何以能通发邪?盖诸病皆系下部虚寒,用之补养肝肾,以益其源,则五脏安利,闭者通而利者止,非若他药轻飘疏通之谓也。现代医学研究表明:山萸肉具有抗菌、调节免疫、降血糖、降血脂、抗氧化、抗癌、抗艾滋病、强心等功能。
白术:味苦;甘;性温。归脾;胃经。健脾益气;燥湿利水;止汗;安胎。主治脾气虚弱;神疲乏力;食少腹胀;大便溏薄;水饮内停;小便不利;水肿;痰饮眩晕;湿痹酸痛;气虚自汗;胎动不安。《本经逢原》载:“术,生用有除湿益燥,消痰利水,治风寒湿痹,死肌痉疸,散腰脐间血,及冲脉为病,逆气里急之功;制熟则有和中补气,止渴生津,止汗除热,进饮食,安胎之效。”现代医学研究证实,白术有强壮和提高机体抗病能力的作用,增强网状内皮系统的吞噬功能,增强白细胞吞噬金黄色葡萄球菌的功能,对白细胞减少症有升白作用,提高淋巴细胞转化率,促进细胞免疫功能,对金黄色葡萄球菌、溶血性链球菌、绿色链球菌、肺炎球菌、脑膜炎球菌、白喉杆菌、枯草杆菌有不同程度的抑制作用,对絮状表皮癣菌、星形奴卡菌、堇色毛癣菌、同心性毛癣菌等皮肤真菌有一定的抑制作用。
黄精:味甘;性平。入脾;肺;肾经。养阴润肺;补脾益气;滋肾填精。主治阴虚劳嗽;肺燥咳嗽;脾虚乏力;食少口干;消渴;肾亏腰膝酸软;阳痿遗精;耳鸣目暗;须发早白;体虚羸瘦;风癞癣疾。《本草逢原》载:“宽中益气,使五藏调和,肌肉充盛,骨髓强坚,皆是补阴之功。”现代医学研究证实,黄精对肾上腺素引起的血糖升高有显著的抑制作用,对常见致病真菌有不同程度的抑制作用,升高肝脏超氧化物歧化酶活性,降低心肌脂褐质含量降低,增强对缺氧的耐受力,此外还有抗病毒功效。
枸杞子:味甘;性平。归肝;肾;肺经。养肝;滋肾;润肺。主治肝肾亏虚;头晕目眩;目视一清;腰膝酸软;阳痿贵精;虚劳咳嗽;消渴引饮。《本草正》载:“明耳目,添精固髓,健骨强筋,善补劳伤,尤止消渴。”现代医学研究证实,枸杞子可调节机体免疫功能、能有效抑制肿瘤生长和细胞突变,具有延缓衰老、抗脂肪肝、调节血脂和血糖、促进造血功能等方面的作用。
茯苓:味甘;淡;性平。入心;脾;肺;肾经。渗湿利水;健脾和胃;宁心安神。主治小便不利;水肿胀满;痰饮咳逆;呕吐;脾虚食少;泄渲;心悸不安;失眠健忘;遗精白浊。《别录》载:“止消渴,好睡,大腹,淋沥,膈中痰水,水肿淋结。开胸腑,调脏气,伐肾邪,长阴,益气力,保神守中。”现代医学研究证实,茯苓对金黄色葡萄球菌、大肠杆菌、变形杆菌等均有抑制作用,能杀死钩端螺旋体等细菌,对消化系统、血液系统及中枢神经系统具有一定的保护作用,此外茯苓聚糖含量很高,可抗肿瘤活性。
黑芝麻:味甘;性平。归肝;脾;肾经。补益肝肾;养血益精;润肠通便。用于头晕眼花,耳鸣耳聋,须发早白,病后脱发,肠燥便秘。现代医学研究证明:黑芝麻具有降血糖作用、促肾上腺作用、抗炎作用及对心血管有一定作用。
当归:味甘;辛;性温。归肝、心、脾经。补血活血;调经止痛;润肠通便。主治血虚萎黄;眩晕心悸;虚寒腹痛;风湿痹痛;跌扑损伤;痈疽疮疡。《本草正》载:“其味甘而重,故专能补血,其气轻而辛,故又能行血,能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。”现代医学研究证实,当归具有抗菌、消炎作用,对慢性风湿关节炎急性发作有明显的抑制作用。
川芎:味辛;性温。归肝;胆;心包经。活血祛瘀;行气开郁;祛风止痛。主治癓瘕肿块;胸胁疼痛;头痛眩晕;风寒湿痹;跌打损伤;痈疽疮疡。《本草正》载:“散风寒,治痛,破瘀蓄,通血脉,解结气,逐疼痛,排脓消肿,逐血通经。”现代医学科学研究发现,川芎提取液对抑制白血病细胞有一定作用,制剂有一定的抗菌作用,尤其是对伤寒杆菌、副伤寒杆菌、霍乱弧菌、绿脓杆菌及致病性皮肤真菌等均有抑制作用,川芎所含的川芎嗪、阿魏酸纳具有活血化瘀功效,可扩张冠状动脉,增进冠脉流量,缓解心绞痛,并具有抗血栓形成作用,所含的川芎内酯有平滑肌解痉和抑制肠肌、子宫收缩等作用。
夜交藤:味甘;微苦;性平。入心;肝经。养心安神;祛风;通络。主治失眠;多梦;血虚身痛;肌肤麻木;风湿痹痛;风疹瘙痒。《饮片新参》载:“养肝肾,止虚汗,安神催眠,补中气,行经络,通血脉,治劳伤。”现代医学研究证实,夜交藤含有大黄素、大黄素甲醚,与戊巴比妥钠呈协同作用,有显著的镇静、催眠作用,尤其是延长慢波睡眠时相。
柏子仁:味甘;性平。归心;肾;大肠经。养心安神;敛汗;润肠通便。主治惊悸怔忡;失眠健忘;盗汗;肠燥便秘。《药品化义》载:“香气透心,体润滋血,主治心神虚怯,惊悸怔忡,颜色憔悴,肌肤燥痒,皆养心血之功也。”现代医学研究证实,柏子仁含有大量不饱和脂肪酸、少量挥发油和多种维生素、皂苷、植物甾醇和蛋白质,提高机体免疫力,多用于治疗变异性心绞痛和风湿性冠心病。
黄芪:味甘;性温。入心;肺;脾;肾经。补气固表;利尿;托毒排脓;生肌敛疮。主治气短心悸;倦怠;乏力;自汗;盗汗;久泻;脱肛;体虚浮肿;子宫脱垂;慢性肾炎;痈疽难溃;或溃久不敛。《新华本草纲要》载:“有补气固表、托毒排脓、生肌的功能。”现代医学研究证实,黄芪主要成分为黄芪总黄酮、黄芪总多糖、黄芪总皂苷和氨基酸等,具有利尿降压、消炎镇痛、强心、抗氧自由基生成及提高机体免疫功能等多种药理作用,可从多方面作用于机体,改善心血管、脑血管、糖尿病、肾病等相关血管性病变患者的血流动力学和血管内皮细胞等功能。
延胡索:味辛;苦;性温;无毒。入肝;胃;心;肺;脾经。活血;散瘀;理气;止痛。主治心腹腰膝诸痛;月经不调;症瘕;崩中;产后血晕;恶露不尽;跌打损伤。《纲目》载:“能行血中气滞,气中血滞,故专治一身上下诸痛,用之中的,妙不可言。活血,利气,止痛,通小便。”现代医学研究表明,延胡索有显著的镇痛、镇静、催眠、安定作用,兴奋胃肠平滑肌,显著扩张冠状血管,能引起垂体促肾上腺皮质激素的分泌,对肌肉有松驰作用。
五味子:味辛;苦;性温。收敛固涩;益气生津;补肾宁心;祛风利湿;理气活血。主治风湿骨痛;跌打损伤;胃痛;月经不调;肾炎。《本经》载:“主益气,咳逆上气,劳伤羸度,补不足,强阴。”现代医学研究证实,五味子含有丰富的有机酸、维生素、类黄酮、植物固醇及有强效复原作用的木酚素,它也是兼具精、气、神三大补益的少数药材之一,能益气强肝、增进细胞排除废物的效率、供应更多氧气、营造和运用能量、提高记忆力及性持久力。
石斛:味甘;性微寒。归胃;肺;肾经。生津益胃;滋阴清热;润肺益肾;明目强腰。主治热病伤津;口干烦渴;胃阴不足;胃痛干呕;肺燥干咳;虚热不退;阴伤目蝉;腰膝软弱。《本草正》载:“石斛益精强阴,壮筋补虚,健脚膝,驱冷痹,却惊悸,定心志,有从容分解之妙,故能退火、养阴、除烦、清肺下气,亦止消渴热汗。”现代医学研究证实,石斛能显著增强巨噬细胞的吞噬作用,能抑制考的松或环磷酰胺所致的免疫,有显著的免疫激活作用,对环磷酰胺所致的白细胞下降有保护作用,并能明显提高鼻咽癌患者NK细胞的活性,能促进唾液、胃液、肠液分泌,能扩张微血管,增加血流,增强心肌收缩力,此外还有解热、镇痛等作用。
牡丹皮:味辛苦;性凉,微寒,归心;肝;肾;肺经。清热;活血散瘀。主治:温热病热入血分;发斑;吐衄;热泪盈眶病菌后期热伏阴分发热;阴虚骨蒸潮热;血滞经闭;痛经;痈肿疮毒;跌扑伤痛;风湿热痹。《本草纲目》:牡丹皮,治手足少阴、厥阴四经血分伏火。盖伏火即阴火也,阴火即相火也,古方惟以此治相火,故仲景肾气丸用之。后人乃专以黄蘖治相火,不知丹皮之功更胜也。赤花者利,白花者补,人亦罕悟,宜分别之。
八月札:昧微苦,性平。归肝、胃、膀胱经。疏肝和胃,活血止痛,软坚散结,利小便。主治肝胃气滞,脘腹、胁助胀痛,饮食不消,下痢便泄,疝气疼痛,腰痛,经闭痛经,瘿瘤瘰疬,恶性肿瘤。《陕西中草药》:疏肝益肾,健脾和胃。治消化不良,腹痛,泻痢,疝气,子宫下坠。
红曲:味甘;性温;无毒。归肝;脾;胃;大肠经。活血化瘀;健脾消食。主治饮食积滞;脘腹胀满;赤白下痢;产后恶露不尽;跌打损伤。《本草衍义补遗》:活血消食,健脾暖胃,赤白痢下水谷。现代医学研究证明:红曲发酵后可分离到辅酶Q10,辅酶Q10又名癸烯醌,是细胞代谢及细胞呼吸的激活剂,能改善线粒体呼吸功能,促进氧化磷酸化反应。它本身又是细胞自身产生的天然氧化剂,能抑制线粒体的过氧化,有保护生物膜结构完整性的功能。对免疫有非特异的增强作用,能提高吞噬细胞的吞噬率,增加抗体的产生,改善T细胞功能。
藿香:味辛;性微温。归脾;胃;肺经。芳香化湿;和胃止呕;祛暑解表。主治湿阻中焦之脘腹痞闵;食欲不振;呕吐;泄泻;外感暑湿之寒热头痛;湿温初起的发热身困;胸闵恶心;鼻渊;手足癣。《本草再新》:"解表散邪,利湿除风,清热止渴。治呕吐霍乱,疟,痢,疮疥。梗:可治喉痹,化痰、止咳嗽。"
甘草:味甘;性平。归心;肺;脾;胃经。补脾益气;清热解毒;祛痰止咳;缓急止痛;调和诸药。主治脾胃虚弱;倦怠乏力;心悸气短;咳嗽痰多;脘腹四脚挛急疼痛;痈肿疮毒;缓解药物毒性。《本草纲目》载:“诸药中甘草为君。治七十二种乳石毒,解一千二百般草本毒,调和从药有功。”现代医学研究证实,甘草有较强的解毒作用,还有抗溃疡、抗炎症、镇痉镇咳、降血压、降血脂、抗癌作用,广泛用于治疗咽喉炎、喉炎、气管炎、支气管炎、哮喘、咳嗽、咳血等疾病,此外还具有抗胃溃疡、抗胃炎作用。
鱼腥草:味辛;性寒。入肝;肺经。清热解毒;排脓消痈;利尿通淋。主治肺痈吐脓;痰热喘咳;喉哦;热痢;痈肿疮毒;热淋。《常用中草药手册》载:“消炎解毒,利尿消肿。治上呼吸道感染,肺脓疡,尿路炎症及其它部位化脓性炎症,毒蛇咬伤。”现代医学研究证实,鱼腥草可以增强WBC的吞噬能力,提高机体免疫力,对各种微生物均有抑制作用,此外还有显著的拮抗、抗病毒、利尿、镇痛、镇咳、止血、抑制浆液分泌、促进组织再生、镇静、抗惊作用。
本发明与现有技术相比,具有以下有益效果:
本发明选用药材,药性相适相辅,针对病因对症下药,有补益肝肾、健脾益气、和胃止呕、活血祛瘀、滋阴清热、清热解毒、理气止痛、养心安神之功效,吸收效果好,疗效显著,无毒副作用及临床不良反应,能提高机体免疫力,改善血液循环,缓解放疗毒副反应,减轻患者痛苦,提高生存质量,达到彻底康复的目的。
具体实施方式
下面结合具体实施例对本发明做进一步阐述。
实施例1
本发明药物有效成分的原料组成及重量为:
麦冬65~82g太子参62~78g大枣59~75g生地55~72g龙眼肉52~68g
山萸肉48~65g白术45~61g黄精43~57g枸杞子40~55g茯苓37~52g
黑芝麻35~49g当归32~46g川芎29~43g夜交藤27~40g柏子仁25~37g
黄芪22~35g延胡索20~32g五味子18~28g石斛15~25g牡丹皮12~21g
八月札10~18g红曲8~15g藿香5~12g甘草3~8g鱼腥草1~5g
本发明药物制备方法的工艺步骤为:
(1)将麦冬、太子参、大枣、生地、山萸肉、黄精、黑芝麻、夜交藤、石斛、牡丹皮、八月札、红曲、藿香、甘草、鱼腥草洗净、晾干后混合均匀,放入容器中,在容器中加入6~8倍量的水,加热煮沸2~3小时,冷却后取浸液;在剩余的药渣中再加入4~6倍量的水,加热煮沸1~2小时,冷却后浸液;合并两次所得浸液,加热,蒸发浓缩为相对密度1.15~1.25的稠膏,备用;
(2)将龙眼肉、枸杞子、茯苓、当归、五味子放入容器中,加入3~5倍量的绍兴黄酒,煮沸后放凉,继续浸泡3~5小时,取浸液;在剩余的药渣中再加入2~4倍量的绍兴黄酒,煮沸后放晾,继续浸泡2~4小时,取浸液;合并两次所得浸液,加蒸蒸发浓缩为相对密度1.10~1.20的稠膏,备用;
(3)将白术、川芎放入铁锅中,文火微炒,炒至表皮变黄后,喷洒即墨老酒,继续炒至表皮焦黄后,取出放凉,粉碎研末,过120目细筛,得细粉,备用;
(4)取黄芪洗净,加定量的米醋拌匀,闷润至醋被吸尽后,置炒制容器内,用文火加热炒干,取出晾凉。筛去碎屑,粉碎研末,过120目细筛,得细粉,备用;
(5)将延胡索洗净晾干,加定量的黄酒拌匀,闷透,文火加热,炒干,取出放凉,粉碎研末,过120目细筛,得细粉,备用;
(6)将柏子仁洗净烘干,粉碎研末,过120目细筛,得细粉,备用;
(7)将步骤(1)、步骤(2)所得的稠膏,与步骤(3)、步骤(4)、步骤(5)、步骤(6)中所得的细粉混合,加入炼蜜搅拌均匀后,制备为每粒8g的药丸。
用法用量:口服,每日3次,每次1丸,饭前一小时以温开水或温黄酒送服,10天为一个疗程。
实施例2
本发明药物有效成分的原料组成及重量为:
麦冬68~78g太子参65~75g大枣62~72g生地58~68g龙眼肉55~65g
山萸肉51~62g白术48~57g黄精46~54g枸杞子43~52g茯苓40~49g
黑芝麻38~46g当归35~43g川芎32~40g夜交藤30~37g柏子仁28~34g
黄芪25~32g延胡索23~29g五味子21~25g石斛18~22g牡丹皮15~19g
八月札12~16g红曲10~13g藿香7~10g甘草4~6g鱼腥草2~4g
本实施例的药物制备方法工艺步骤及用法用量与实施例1相同。
实施例3
本发明药物有效成分的原料组成及重量为:
麦冬75g太子参72g大枣68g生地64g龙眼肉61g
山萸肉58g白术54g黄精51g枸杞子48g茯苓45g
黑芝麻42g当归38g川芎35g夜交藤33g柏子仁31g
黄芪28g延胡索25g五味子23g石斛20g牡丹皮17g
八月札14g红曲12g藿香8g甘草5g鱼腥草3g
本实施例的药物制备方法工艺步骤及用法用量与实施例1相同。
临床资料:
1、病例选择
选择我院接诊的患者80例临床观察,病人随机分成两组。治疗组40例,其中男性25例,女性15例,年龄42~75岁,平均年龄62.3岁。对照组40例,其中男性24例,女性16例,年龄44~77岁,平均年龄61.4岁。两组资历基本一致,无显著差异,具有可比性。
2、治疗组患者服用本发明药物,口服,每日3次,每次1丸,饭前一小时以温开水或温黄酒送服,10天为一个疗程。对照组根据诊断出的肿瘤放疗后反应症状,分别予以传统的西医治疗手段。
3、疗效判定:
(1)治愈:放疗后反应症状基本消失,身体状况明显增强。
(2)好转:放疗后反应症状明显缓解,身体状况有所好转。
(3)无效:症状同施治前无明显差异。
4、结果
治疗组中治愈27例,好转9例,无效4例,治愈率67.5%,总有效率90%。
对照组中治愈12例,好转19例,无效9例,治愈率30%,总有效率77.5%。
以上结果显示,治疗组的治愈率和总有效率明显高于对照组。
典型病例举例:
1、孙××,男,55岁。该患者因肿瘤接受放疗后,出现面色苍白、头昏目眩、毛发干枯、食欲减退、呕吐、嗜睡口渴等反应症状,服用本发明的药物,口服,每日3次,每次1丸,饭前一小时以温开水送服,10天为一个疗程。服用2个疗程后,不良反应症状完全消失,身体状况明显好转。
2、王××,女,68岁。患者因肿瘤接受放疗后,出现身体乏力、心慌气短、踡卧嗜睡、口燥咽干、午后潮热等不良症状,服用本发明的药物,口服,每日3次,每次1丸,饭前一小时以温开水送服,10天为一个疗程。经服用3个疗程后,不良反应症状完全消失,身体状况明显好转。
本发明所述的药丸是经长期临床验证总结配置而成,药材的药性相适相辅,针对病因对症下药,方中太子参、白术、黄精等中药可健脾益气、养阴润肺;方中大枣、茯苓等中药可健脾和胃、养心安神;方中山萸肉、枸杞子、黑芝麻等中药可养肝滋肾、养血益精;方中当归可补血活血;方中石斛、生地、麦冬等中药可滋阴清热、润肺清心;方中延胡索、川芎等中药可活血祛瘀、理气止痛;方中黄芪、五味子等中药可补气固表、生肌敛疮;方中鱼腥草、牡丹皮等中药可清热解毒;方中红曲、藿香等中药可健脾消食、和胃止呕;方中甘草可祛痰止咳、调和诸药;方中诸药合用,可扶正固本、健脾养阴、活血化瘀、清热解毒,能提高机体免疫力,改善血液循环,减轻患者痛苦,有效的缓解放疗的毒副反应,提高生存质量,达到彻底康复的目的。
Claims (4)
1.一种用于缓解肿瘤放疗后反应的中药药丸,其特征在于:制成所述药物有效成分的原料组成及重量份数为:
麦冬65~82g太子参62~78g大枣59~75g生地55~72g龙眼肉52~68g
山萸肉48~65g白术45~61g黄精43~57g枸杞子40~55g茯苓37~52g
黑芝麻35~49g当归32~46g川芎29~43g夜交藤27~40g柏子仁25~37g
黄芪22~35g延胡索20~32g五味子18~28g石斛15~25g牡丹皮12~21g
八月札10~18g红曲8~15g藿香5~12g甘草3~8g鱼腥草1~5g。
2.根据权利要求1所述的一种用于缓解肿瘤放疗后反应的中药药丸,其特征在于:制成所述药物有效成分的原料组成及重量份数为:
麦冬68~78g太子参65~75g大枣62~72g生地58~68g龙眼肉55~65g
山萸肉51~62g白术48~57g黄精46~54g枸杞子43~52g茯苓40~49g
黑芝麻38~46g当归35~43g川芎32~40g夜交藤30~37g柏子仁28~34g
黄芪25~32g延胡索23~29g五味子21~25g石斛18~22g牡丹皮15~19g
八月札12~16g红曲10~13g藿香7~10g甘草4~6g鱼腥草2~4g。
3.根据权利要求1所述的一种用于缓解肿瘤放疗后反应的中药药丸,其特征在于:制成所述药物有效成分的原料组成及重量份数为:
麦冬75g太子参72g大枣68g生地64g龙眼肉61g
山萸肉58g白术54g黄精51g枸杞子48g茯苓45g
黑芝麻42g当归38g川芎35g夜交藤33g柏子仁31g
黄芪28g延胡索25g五味子23g石斛20g牡丹皮17g
八月札14g红曲12g藿香8g甘草5g鱼腥草3g。
4.一种用于缓解肿瘤放疗后反应的中药药丸的制备方法,其特征在于:包括以下工艺步骤:
(1)将麦冬、太子参、大枣、生地、山萸肉、黄精、黑芝麻、夜交藤、石斛、牡丹皮、八月札、红曲、藿香、甘草、鱼腥草洗净、晾干后混合均匀,放入容器中,在容器中加入6~8倍量的水,加热煮沸2~3小时,冷却后取浸液;在剩余的药渣中再加入4~6倍量的水,加热煮沸1~2小时,冷却后浸液;合并两次所得浸液,加热,蒸发浓缩为相对密度1.15~1.25的稠膏,备用;
(2)将龙眼肉、枸杞子、茯苓、当归、五味子放入容器中,加入3~5倍量的绍兴黄酒,煮沸后放凉,继续浸泡3~5小时,取浸液;在剩余的药渣中再加入2~4倍量的绍兴黄酒,煮沸后放晾,继续浸泡2~4小时,取浸液;合并两次所得浸液,加蒸蒸发浓缩为相对密度1.10~1.20的稠膏,备用;
(3)将白术、川芎放入铁锅中,文火微炒,炒至表皮变黄后,喷洒即墨老酒,继续炒至表皮焦黄后,取出放凉,粉碎研末,过120目细筛,得细粉,备用;
(4)取黄芪洗净,加定量的米醋拌匀,闷润至醋被吸尽后,置炒制容器内,用文火加热炒干,取出晾凉。筛去碎屑,粉碎研末,过120目细筛,得细粉,备用;
(5)将延胡索洗净晾干,加定量的黄酒拌匀,闷透,文火加热,炒干,取出放凉,粉碎研末,过120目细筛,得细粉,备用;
(6)将柏子仁洗净烘干,粉碎研末,过120目细筛,得细粉,备用;
(7)将步骤(1)、步骤(2)所得的稠膏,与步骤(3)、步骤(4)、步骤(5)、步骤(6)中所得的细粉混合,加入炼蜜搅拌均匀后,制备为每粒8g的药丸。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510718052.7A CN105148039A (zh) | 2015-10-28 | 2015-10-28 | 一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510718052.7A CN105148039A (zh) | 2015-10-28 | 2015-10-28 | 一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105148039A true CN105148039A (zh) | 2015-12-16 |
Family
ID=54789303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510718052.7A Pending CN105148039A (zh) | 2015-10-28 | 2015-10-28 | 一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105148039A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497576A (zh) * | 2015-12-18 | 2016-04-20 | 夏修菲 | 一种用于缓解和治疗老年眩晕征的中药丸剂及制备方法 |
| CN105749071A (zh) * | 2016-04-02 | 2016-07-13 | 张茂英 | 一种缓解乳腺肿瘤放疗后反应的药物及其制备方法 |
| CN105796929A (zh) * | 2016-03-23 | 2016-07-27 | 青岛大学附属医院 | 一种缓解肿瘤放疗后反应的药物及其制备方法 |
| CN107802482A (zh) * | 2017-11-17 | 2018-03-16 | 山东恒健康体养生保健有限公司 | 一种激活天然免疫治疗慢病的康复方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263587A (zh) * | 2013-04-27 | 2013-08-28 | 李永团 | 一种治疗鼻咽癌放疗后毒副作用的中药制剂及制备方法 |
| CN104258203A (zh) * | 2014-10-22 | 2015-01-07 | 陈洁 | 一种用于防治放疗引起白细胞减少的中药组合物 |
| CN104740304A (zh) * | 2015-04-02 | 2015-07-01 | 霍明昌 | 一种用于治疗肩周炎的中药丸剂及制备方法 |
-
2015
- 2015-10-28 CN CN201510718052.7A patent/CN105148039A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263587A (zh) * | 2013-04-27 | 2013-08-28 | 李永团 | 一种治疗鼻咽癌放疗后毒副作用的中药制剂及制备方法 |
| CN104258203A (zh) * | 2014-10-22 | 2015-01-07 | 陈洁 | 一种用于防治放疗引起白细胞减少的中药组合物 |
| CN104740304A (zh) * | 2015-04-02 | 2015-07-01 | 霍明昌 | 一种用于治疗肩周炎的中药丸剂及制备方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497576A (zh) * | 2015-12-18 | 2016-04-20 | 夏修菲 | 一种用于缓解和治疗老年眩晕征的中药丸剂及制备方法 |
| CN105796929A (zh) * | 2016-03-23 | 2016-07-27 | 青岛大学附属医院 | 一种缓解肿瘤放疗后反应的药物及其制备方法 |
| CN105749071A (zh) * | 2016-04-02 | 2016-07-13 | 张茂英 | 一种缓解乳腺肿瘤放疗后反应的药物及其制备方法 |
| CN107802482A (zh) * | 2017-11-17 | 2018-03-16 | 山东恒健康体养生保健有限公司 | 一种激活天然免疫治疗慢病的康复方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105687824A (zh) | 一种用于治疗产后盗汗的中药冲剂及制备方法 | |
| CN104524440B (zh) | 一种用于女性内分泌紊乱调理的药丸及制备方法 | |
| CN105148039A (zh) | 一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 | |
| CN104771729A (zh) | 一种用于肺癌辅助治疗的中药丸剂及制备方法 | |
| CN103432412A (zh) | 一种治疗乳腺增生的药物及其制备方法 | |
| CN105497784A (zh) | 一种用于治疗血栓性浅静脉炎的中药丸剂及制备方法 | |
| CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
| CN105267757A (zh) | 一种用于产后自汗治疗与护理的中药丸剂及制备方法 | |
| CN105456661A (zh) | 一种用于治疗放射性皮炎的中药冲剂及制备方法 | |
| CN105362834A (zh) | 一种用于治疗产后伤食的中药丸剂及制备方法 | |
| CN105343866A (zh) | 一种用于治疗寒饮咳嗽的中药片剂及制备方法 | |
| CN105999110A (zh) | 一种用于治疗女性慢性盆腔疼痛的中药冲剂及制备方法 | |
| CN104840874A (zh) | 一种用于动脉瘤术后康复治疗的中药丸剂及制备方法 | |
| CN105267696A (zh) | 一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 | |
| CN104740304A (zh) | 一种用于治疗肩周炎的中药丸剂及制备方法 | |
| CN105381128A (zh) | 一种辅助针灸治疗外周神经麻痹的中药冲剂及制备方法 | |
| CN105288427A (zh) | 一种用于治疗肝郁气滞型胃潴留的中药丸剂及制备方法 | |
| CN105250569A (zh) | 一种用于治疗末梢神经炎的中药丸剂及制备方法 | |
| CN104940885A (zh) | 一种治疗内分泌功能紊乱的中药 | |
| CN103990019A (zh) | 一种治疗头晕目眩的中药药剂 | |
| CN105434934A (zh) | 一种用于治疗妇科更年期综合症的中药丸剂及制备方法 | |
| CN105497782A (zh) | 一种用于治疗肾石症的中药丸剂及制备方法 | |
| CN105434932A (zh) | 一种用于治疗女性性早熟综合征的中药丸剂及制备方法 | |
| CN105148038A (zh) | 一种用于治疗ct检查后不良反应的中药丸剂及制备方法 | |
| CN105535461A (zh) | 一种用于防治小儿风热型感冒的中药片剂及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151216 |